|NASDAQ: CNCE||Healthcare / Biotechnology / USA|
|8.37||+0.0100||+0.12%||Vol 9.98M||1Y Perf 200.72%|
|Mar 3rd, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||19.00||Analyst Rating||Moderate Buy 2.00|
|Potential %||-||Finscreener Ranking||★★★★ — -|
|Insiders Trans % 3/6/12 mo.||100/-25/-63||Value Ranking||★★+ 48.48|
|Insiders Value % 3/6/12 mo.||100/84/64||Growth Ranking||★★★★ — -|
|Insiders Shares Cnt. % 3/6/12 mo.||100/76/51||Income Ranking||— -|
|Price Range Ratio 52W %||98.79||Earnings Rating||Sell|
|Market Cap||401.94M||Earnings Date||9th Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.59|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.00M|
|Avg. Monthly Volume||1.51M|
|Avg. Quarterly Volume||1.98M|
Concert Pharmaceuticals Inc. (NASDAQ: CNCE) stock closed at 8.37 per share at the end of the most recent trading day (a 0.12% change compared to the prior day closing price) with a volume of 9.98M shares and market capitalization of 401.94M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 71 people. Concert Pharmaceuticals Inc. CEO is Roger D. Tung.
The one-year performance of Concert Pharmaceuticals Inc. stock is 200.72%, while year-to-date (YTD) performance is 43.32%. CNCE stock has a five-year performance of -62.5%. Its 52-week range is between 2.66 and 8.44, which gives CNCE stock a 52-week price range ratio of 98.79%
Concert Pharmaceuticals Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 2.69, a price-to-sale (PS) ratio of 12 216.00, a price to cashflow ratio of 3.40, a PEG ratio of 2.32, a ROA of -90.57%, a ROC of -96.72% and a ROE of -116.61%. The company’s profit margin is -%, its EBITDA margin is -292 864.00%, and its revenue ttm is $29.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Concert Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.59 for the next earnings report. Concert Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Concert Pharmaceuticals Inc. is Moderate Buy (2), with a target price of $19, which is 0.00% compared to the current price. The earnings rating for Concert Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Concert Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Concert Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.41, ATR14 : 0.12, CCI20 : 175.24, Chaikin Money Flow : -0.39, MACD : 0.21, Money Flow Index : 65.76, ROC : 0.36, RSI : 66.65, STOCH (14,3) : 21.74, STOCH RSI : 0.12, UO : 27.44, Williams %R : -78.26), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Concert Pharmaceuticals Inc. in the last 12-months were: James V. Cassella (Sold 16 761 shares of value $136 734 ), Jeffrey A. Munsie (Sold 15 148 shares of value $123 266 ), Marc Evan Becker (Sold 15 148 shares of value $123 228 ), Nancy Stuart (Sold 22 141 shares of value $181 574 ), Peter Barton Hutt (Option Excercise at a value of $10 192), Peter Barton Hutt (Sold 3 539 shares of value $21 553 ), Richard H. Aldrich (Buy at a value of $999 999), Roger D. Tung (Sold 9 240 shares of value $66 898 ), Thomas G. Auchincloss (Buy at a value of $28 500), Van Christi Heek (Buy at a value of $49 999)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Strong Buy|
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the current approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.
CEO: Roger D. Tung
Telephone: +1 781 860-0045
Address: 65 Hayden Avenue, Lexington 02421, MA, US
Number of employees: 71
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.